MetaCap

Anbio Biotechnology (NNNN) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Achieve Life Sciences is the larger company by market cap ($573.2 million vs $145.7 million), about 3.9 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NNNN-60.87%QUIT-25.87%
+18%-25%-67%
Aug 17, 20261 yearNov 20, 2026
NNNN-51.25%QUIT-30.41%
+16%-21%-57%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NNNN versus QUIT key metrics
MetricNNNNQUIT
Share price$3.32$5.56
Market cap$145.72M$573.25M
1-day change-9.04%-5.28%
YTD return-88.96%—
1-year return-86.02%—
P/E ratio (TTM)22.13—
EPS (TTM)$0.15$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.65M—
Revenue growth (YoY)+5.64%—
Net income (latest FY)$6.40M$-54.65M
Gross margin87.24%—
Operating margin66.70%—
Net margin74.06%—
52-week high$44.73$8.64
52-week low$3.09$2.62
Distance from 52-week high-92.58%-35.65%
Analyst consensus—strong_buy
Avg. price target upside—+162.23%
Average volume128.35K1.38M
Shares outstanding43.89M103.10M
Employees2728
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Achieve Life Sciences is about 3.9 times larger than Anbio Biotechnology by market value ($573.25M vs $145.72M).

About Anbio Biotechnology

NNNN stock →

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

NNNN vs QUIT FAQ

Which is bigger, Anbio Biotechnology or Achieve Life Sciences?

Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $145.72M for Anbio Biotechnology (NNNN).

Are Anbio Biotechnology and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons